All articles by GlobalData

Blood matching tests by the NHS may improve blood transfusion outcomes

According to the National Institute for Health and Care Excellence (NICE), sickle cell disease, a group of inherited diseases that…
Is raising mental health awareness causing more harm than good?

While raising mental health awareness is undoubtedly a positive step towards reducing stigma and promoting open conversations about mental health,…
Risk of chronic conditions associated with heavy alcohol intake in Chinese men

Controlled alcohol consumption does not pose any immediate danger to the public’s general health; however, excessive and persistent drinking can…
BioCardia submits Japan application for CardiAMP to treat ischemic HFrEF

BioCardia recently announced that it had submitted its leading product, CardiAMP, to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). CardiAMP…
Artificial intelligence advances cancer diagnostics in the next decade

In GlobalData’s Clinical Trials Database, there are currently 1,490 active clinical trials for in vitro diagnostics (IVD) devices, where 569…

Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo

Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy…
Chinese checkpoint inhibitors are poised to change global IO markets

The Chinese Government’s significant R&D investments in recent years has resulted in the successful commercialisation and launch of several domestically…
Turning point: November marked by promising Covid-19 vaccine development data

With the global devastation of Covid-19 continuing into 2021, the month of November marks a turning point in the pandemic…
Jardiance fails to deliver in EMPERIAL trials for heart failure

Boehringer Ingelheim and Eli Lilly’s collaborative effort to secure Jardiance’s (empagliflozin’s) place in the heart failure (HF) landscape has reached…
Astellas expands into gene therapy with $3bn acquisition of Audentes

California-based Audentes is a clinical-stage company that focuses on developing adeno-associated virus (AAV)-based gene therapies for serious rare neuromuscular diseases.…